Ongoing Trials

    Colorectal Cancer

    Dec 04, 2017 by Corporate

    Blood draw and tissue collection for men and women ages 19-80 who have, or are suspected of having Colorectal cancer. Patient should have surgery pending or scheduled.

    Continue Reading

    Pulmonary Hypertension

    Dec 04, 2017 by Corporate

    We have a number of Pulmonary Hypertension studies that are ongoing. But due to the nature of these trials please contact us if you are interested in participating.

    Continue Reading

    OB/GYN

    Dec 04, 2017 by Corporate

    Single Blood draw for women 10-26 months pregnant Urine collection for women ages 18-40, who are 1-9 months pregnant Urine collection for non-pregnant women 18-40

    Continue Reading

    Neurology Trial: 36 week study phase 2 study to assess the effect of drug on functional decline in subjects with ALS

    Dec 04, 2017 by Corporate

    INCLUSION: Male/ Female 18-75 years of age Clinically definite, laboratory probable, or clinically probable ALS ALS symptom onset < 2 years prior to screening visit Subjects on riluzole may enter the study if they have been on a stable dose of 50mg BID for >4 weeks prior to screening visit. EXCLUSION: Subject has participated in

    Continue Reading

    Neurology Trial: 16 week study designed to assess the effect of the drug versus placebo on respiratory function with patients with ALS

    Dec 04, 2017 by Corporate

    INCLUSION: Male/Female 18-80 years of age Sporadic or familial ALS <24 months prior to screening SVC > 65% of predicted for age/height/sex EXCLUSION: At time of screening any use of non-invasive ventilation Neurological impairment due to a condition other than ALS Presence at screening of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness

    Continue Reading

    Neurology Trial: 28 Week study designed to test efficacy of a fixed combination of drugs for the treatment of ALS

    Dec 04, 2017 by Corporate

    INCLUSION: Male/Female 18-80 years of age Sporadic or familial ALS Less than or equal to 18 months since ALS symptom onset. Slow Vital Capacity >60% of predicted value for gender/height/age at screening EXCLUSION: Presence of tracheostomy Exposure to PB/ TUDCA, or UDCA within 3 months prior to the Screening visit

    Continue Reading

    Asthma Trial: Observational study of patients with a diagnosis of asthma and/or COPD (observation period of 3 years)

    Nov 27, 2017 by Corporate

    a. Subjects ≥12 years of age with a confirmed or suspected diagnosis of asthma or COPD b. Observational study only (no study medications)

    Continue Reading

    Asthma Trial: Pediatric 6-12 years with persistent, uncontrolled asthma (treatment period of 52 weeks)

    Nov 27, 2017 by Corporate

    a. Subjects 6-12 years of age with persistent asthma for at least 12 months b. At least 3 months of therapy on medium-dose inhaled corticosteroids plus a second asthma controller or high-dose inhaled corticosteroids alone c. One or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids

    Continue Reading

    Asthma Trial: Patients with severe, uncontrolled asthma (treatment period of 24 weeks)

    Nov 27, 2017 by Corporate

    a. Subjects 18-75 years of age with severe asthma requiring medium to high-dose inhaled corticosteroids plus a second asthma controller in the previous 12 months b. Two or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids c. Pre-screening FEV1 <80% of predicted d. Current smokers and ex-smokers with >10 pack-year

    Continue Reading

    Asthma Trial: Patients with severe, uncontrolled asthma (treatment period of 52 weeks)

    Oct 28, 2016 by Corporate

    a. Subjects ≥12 years of age with severe asthma requiring medium to high-dose inhaled corticosteroids plus a second or third asthma controller b. Two or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids c. FEV1 of ≥40% and ≤80% (≤90% for patients aged 12-18 years) d. Current smokers and ex-smokers

    Continue Reading